Belantamab Mafodotin Combination Therapy
A Phase I/II Study of the Safety, Tolerability and Efficacy of Belantamab Mafodotin (GSK2857916) in Combination With Iberdomide (CC-220)/Dexamethasone Versus Belantamab Mafodotin (GSK2857916)/Dexamethasone in Relapsed Refractory Multiple Myeloma
More Information
- Trial Status
- Not yet accepting
- Trial Phase
- Phase 1/2
- Enrollment
- 88 patients (estimated)
- Sponsors
- Alliance for Clinical Trials in Oncology
- Collaborators
- National Cancer Institute (NCI)
- Tags
- Antibody Drug Conjugate (ADC), B-Cell Maturation Antigen (BCMA), Randomization
- Trial Type
- Treatment
- Last Update
- 2 days ago
- SparkCures ID
- 2040
- NCT Identifier
- NCT06232044
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print a patient-friendly report to share with your patient.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.